RT Journal Article
SR Electronic
T1 Oxytocin reduces subjective fear in naturalistic social contexts via enhancing top-down middle cingulate-amygdala regulation and brain-wide connectivity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.22.24306196
DO 10.1101/2024.04.22.24306196
A1 Fu, Kun
A1 Xu, Shuyue
A1 Zhang, Zheng
A1 Liu, Dan
A1 Xu, Ting
A1 Zhang, Yuan
A1 Zhou, Feng
A1 Zhang, Xiaodong
A1 Lan, Chunmei
A1 Wang, Junjie
A1 Wang, Lan
A1 He, Jingxian
A1 Kendrick, Keith M
A1 Biswal, Bharat
A1 Liang, Zhen
A1 Zhao, Weihua
A1 Becker, Benjamin
YR 2024
UL http://medrxiv.org/content/early/2024/04/23/2024.04.22.24306196.abstract
AB Accumulating evidence from animal and human studies suggests a fear-regulating potential of the neuropeptide oxytocin (OT), yet the clinical translation into novel interventions for pathological fear requires a behavioral and neurofunctional characterization under close-to-real life conditions. Here, we combined a naturalistic fMRI-design inducing high and immersive fear experience in social and non-social contexts with a preregistered between-subjects randomized double-blind placebo-controlled intranasal OT trial (24 IU, n = 67 healthy men). OT reduced subjective fear in non-social and social contexts with small or moderate effect sizes, respectively. In the social fear contexts, OT enhanced left middle cingulate cortex (lMCC) activation and its functional connectivity with the contralateral amygdala, with both neural indices significantly and inversely associated with subjective fear following OT. On the network level, OT enhanced communication between the dorsal attention network (DAN) with the fronto-parietal (FPN) and the default-mode network (DMN) as well as on the more fine-grained level brain-wide communication. These findings indicate a fear-reducing potential of OT under naturalistic conditions with pronounced effects in social contexts, suggesting a high treatment value in disorders with social context-related excessive fear.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05892939Funding StatementThis work was supported by the China MOST2030 Brain Project (Grant No. 2022ZD0208500), the National Natural Science Foundation of China (Grants No. 32250610208, 82271583-BB), the National Key Research and Development Program of China (Grant No. 2018YFA0701400-BB), the Natural Science Foundation of Sichuan Province (Grant number 2022NSFSC1375-WZ) and a start-up grant from The University of Hong Kong.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the University of Electronic Science and Technology of China gave ethical approval for this work (UESTC-1061423041725893)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author